What are the guidelines for neuromuscular monitoring in a surgical setting where neuromuscular blocking agents (NMBAs) are used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neuromuscular Monitoring in Surgical Settings

Core Recommendation

Quantitative neuromuscular monitoring is essential and must be used whenever neuromuscular blocking agents are administered, from before initiation of blockade until train-of-four (TOF) ratio >0.9 is confirmed before extubation. 1


Equipment and Setup Requirements

Every operating theatre where NMBAs are used must be equipped with a quantitative neuromuscular monitoring device. 1 The monitor should be:

  • Applied along with other essential monitoring 1
  • Activated after induction of general anesthesia but before neuromuscular blockade 1, 2
  • Used throughout all phases of anesthesia until adequate recovery is documented 1

Monitoring Site Selection

The ulnar nerve with thumb adduction (adductor pollicis) is the most reliable and recommended monitoring site. 1, 2

Alternative Sites When Ulnar Nerve Monitoring Is Not Feasible

If thumb movement is impeded (e.g., hand inaccessible during surgery), readings become unreliable with acceleromyography devices. 1, 2 In these situations:

  • Consider electromyography (EMG) devices 1
  • Use compressomyography devices (TOF-Cuff) 1, 2
  • Monitor alternative sites such as facial or tibial nerve 1

Critical caveat: If facial nerve monitoring is used, the risk of residual paralysis is five times greater—revert to ulnar nerve stimulation at the end of surgery. 1, 2


Understanding the "Monitoring Gap"

Clinical assessment and qualitative peripheral nerve stimulation cannot guarantee adequate recovery. 1 Here's why:

  • Absence of tactile or visible TOF fade only indicates TOF ratio recovery to ≥0.4 1
  • The critical "monitoring gap" exists between TOF ratio 0.4 and 0.9—only quantitative monitoring can assess this range 1, 2
  • Clinical tests (sustained head-lift, hand grip, tongue depressor) have sensitivities of only 10-30% and positive predictive values <50% 1, 2
  • Clinical signs (spontaneous respiration, adequate tidal breaths, coughing, extremity movements) do not exclude residual blockade 1

Train-of-Four Interpretation

Four electrical stimuli are delivered in rapid succession; with increasing blockade depth, twitches decrease progressively: T4 is lost first, then T3, T2, and finally T1. 2

Dosing Guidelines Based on TOF Response

When using reversal agents, timing depends on the degree of spontaneous recovery:

  • If TOF shows 1-2 post-tetanic counts (PTC) with no twitch responses: 4 mg/kg sugammadex for rocuronium/vecuronium 3
  • If second twitch (T2) has reappeared: 2 mg/kg sugammadex 3
  • For immediate reversal (approximately 3 minutes after rocuronium 1.2 mg/kg): 16 mg/kg sugammadex 3

For neostigmine:

  • When first twitch is substantially >10% of baseline or second twitch present: 0.03 mg/kg IV 4
  • When first twitch is close to 10% of baseline: 0.07 mg/kg IV (maximum 5 mg total) 4

Extubation Criteria

A TOF ratio >0.9 must be demonstrated and documented before patient awakening and extubation. 1, 2 This is non-negotiable because:

  • Residual neuromuscular blockade (TOF <0.9) has a reported incidence of 4-64% 1
  • Harmful consequences include generalized muscle weakness, delayed recovery, reduced hypoxic responsiveness, aspiration risk, postoperative pulmonary complications, and accidental awareness during general anesthesia 1
  • One study showed 37% of patients entering recovery ≥2 hours after a single 2×ED95 dose had TOF ratios <0.9 1
  • A 2021 prospective study found 48.8% of patients were extubated without adequate recovery (TOF <0.9) 5

Special Considerations and Technical Pitfalls

Patient Factors That Affect Monitoring Accuracy

Multiple factors can influence TOF monitoring results: 1, 2

  • Monitoring site location (response differs between adductor pollicis, orbicularis oculi, and respiratory muscles due to varying nicotinic receptor density) 1, 2
  • Patient temperature (hypothermia can cause inadequate response despite ventilator dyssynchrony) 1
  • Peripheral edema (may require ultrasound guidance to locate the ulnar nerve) 1, 2
  • Diaphoresis and skin resistance 1, 2

Equipment Variability

Different brands of peripheral nerve stimulator devices vary in the amount of current delivered and whether precise milliamperes are displayed. 1 This creates challenges when patients transfer between units with different equipment. 1


Integration with Clinical Assessment

Quantitative monitoring must be incorporated into a comprehensive patient assessment that includes clinical evaluation—TOF monitoring alone should not be the sole determinant. 1, 2

In the ICU setting specifically, guidelines suggest against using peripheral nerve stimulation with TOF alone, recommending it only as part of a more inclusive assessment. 1 However, in the surgical/anesthesia setting, quantitative monitoring is mandatory and takes precedence. 1


Documentation Requirements

Adequacy of recovery (TOF ratio >0.9) should be documented before patient awakening and extubation. 1 An accurate anaesthetic record should be made with information from all monitoring devices, preferably using automated electronic systems integrated into the hospital's electronic health record. 1


Special Populations

Succinylcholine and Mivacurium

Quantitative monitoring should be used even with short-acting agents like succinylcholine and mivacurium. 1 A Danish registry showed higher incidence of premature awakening, residual paralysis, and re-intubation in unmonitored patients with butyrylcholinesterase deficiency. 1

Severe Renal Impairment

Sugammadex is not recommended in patients with severe renal impairment. 3 Waiting times for re-administration of NMBAs after reversal with sugammadex should be based on the dose used and the patient's renal function. 3


Consequences of Inadequate Monitoring

Residual neuromuscular blockade is associated with: 2

  • Higher morbidity and mortality within the first 24 hours postoperatively 2
  • Greater risk of critical respiratory events in the recovery room 2
  • Increased risk of postoperative pneumonia 2
  • Pharyngeal muscle dysfunction 2
  • Delayed discharge from the recovery room 2

A 2021 observational study found a 5.4% rate of postoperative respiratory complications in the first 24 hours, with hypoxemia being most common. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Accelerography in Neuromuscular Blockade Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.